Diagnosis, Treatment and Prognosis of Prostate Cancer

Dear Colleagues,

Prostate cancer is the most common non-skin cancer in men and the second leading cause of cancer-related deaths among men worldwide. The understanding and management of prostate cancer have evolved significantly over the past few decades. Early detection through PSA (prostate-specific antigen) testing has transformed the landscape of prostate cancer diagnosis, allowing for earlier and more effective intervention. However, challenges remain in differentiating between indolent and aggressive forms of the disease, leading to a need for more precise diagnostic tools and treatment strategies. Treatment approaches have diversified, ranging from active surveillance for low-risk cases to advanced therapies such as targeted therapy, immunotherapy, and robotic-assisted surgery for high-risk and metastatic prostate cancer. The focus on prognosis has also intensified, with ongoing research into biomarkers and genetic profiling aiming to predict disease progression more accurately and tailor treatment to individual patients.

The aim of this Special Issue is to compile the latest research and expert reviews on the diagnosis, treatment, and prognosis of prostate cancer. This issue will cover a wide range of topics, from advancements in early detection and imaging techniques to novel treatment modalities and prognostic tools that enhance the ability to predict outcomes. The scope includes developments in understanding the molecular underpinnings of prostate cancer as well as innovative approaches to managing and treating different stages of the disease, from localized to advanced metastatic prostate cancer.

This Special Issue is intended to serve as a valuable resource for clinicians, researchers, and healthcare professionals involved in the care of prostate cancer patients. It will also be of interest to policymakers and educators seeking to stay informed on the latest developments in this rapidly evolving field.

Dr. Juan Gómez Rivas
Dr. Jesús Moreno Sierra
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.